Currently trading with a volume of 421,493, the REGN's price is down by 0.0%, now at $1040.27. RSI readings suggest the stock ...

The increasing incidence of respiratory conditions like asthma, COPD, and bronchitis mainly drives the growth of the inhalable drugs market. Additionally, the rising prevalence of diabetes and ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

Sanofi and Regeneron have announced that dupilumab has received FDA approval as an add-on maintenance treatment for adults ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...